ArticleJournal for immunotherapy of cancer2024
Correction: ASCC3 promotes the immunosuppression and progression of non-small cell lung cancer by impairing the type I interferon response via CAND1-mediated ubiquitination inhibition of STAT3.
PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.